高级检索
当前位置: 首页 > 详情页

Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Jilin Canc Hosp, Dept Thorac Oncol, Jilin, Peoples R China [2]Zhengzhou Univ, Affiliated Canc Hosp, Inst Canc Res, Dept Internal Med, Zhengzhou, Peoples R China [3]Henan Acad Innovat Med Sci, Henan Canc Hosp, Zhengzhou, Peoples R China [4]Beijing Canc Hosp, Beijing, Peoples R China [5]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China [6]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha, Peoples R China [7]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China [8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [9]China Med Univ, Hosp 1, Shenyang, Peoples R China [10]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Affiliated Canc Hosp,Key Lab Sich, Chengdu, Peoples R China [11]Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China [12]Liaoning Canc Hosp, Shenyang, Liaoning, Peoples R China [13]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China [14]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [15]Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China [16]Army Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China [17]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China [18]AstraZeneca, Shanghai, Peoples R China [19]AstraZeneca, New York, NY USA [20]Univ Amsterdam, Vrije Univ Amsterdam, Canc Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands
出处:
ISSN:

摘要:
Background: The global, phase III, double-blind ADRIATIC trial (NCT03703297) assessed D ± tremelimumab (T) vs placebo (P) as consolidation therapy for patients (pts) with LS-SCLC who had not progressed after concurrent chemoradiotherapy (cCRT). At the first interim analysis (data cutoff 15 Jan 2024), D significantly improved overall survival (OS; hazard ratio [HR] 0.73 [95% CI 0.57–0.93]; p = 0.0104) and progression-free survival (PFS; HR 0.76 [95% CI 0.61– 0.95]; p = 0.0161) vs P; the D+T arm remained blinded. We report a prespecified subgroup analysis of D vs P in pts enrolled in China.

基金:
语种:
WOS:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区:
出版当年[2025]版:
最新[2023]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Jilin Canc Hosp, Dept Thorac Oncol, Jilin, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:57692 今日访问量:2 总访问量:4768 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号